Nursing experience of gosartumumab treatment in patients with triple-negative breast cancer
戈沙妥珠单抗治疗在三阴性乳腺癌患者治疗中的护理体会

摘要

近年来，随着妇女在社会家庭中发挥的作用越来越大，压力也随之增加，导致乳腺癌的发病率持续攀升。乳腺癌：女性常见疾病类别，发病率高居女性恶性肿瘤之首，主要是乳腺上皮细胞在多种致癌因子的作用下，发生增值失控的现象，需积极、尽早的开展治疗，否则可威胁患者生命安全。三阴性乳腺癌：主要指癌组织中雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体-2（HER-2）均为阴性的乳腺癌，可在所有乳腺癌中占比15％-20％，最为常见的类型是浸润性导管癌（髓样癌、腺样囊性癌、化生性癌）等，该病症具备复发转移率高、中位生存期短、预后较差类特征，是临床治疗较为棘手的一种。庆幸的是，我们所处当下科学发达、医疗技术先进的时代，多数疾病均可通过高超的医疗手段得以控制和解除，戈沙妥珠单抗是全球首个获批的靶向滋养细胞表面抗原2的抗体偶联药物，具备安全性高、疗效显著、不良反应少的优势，这也为三阴性乳腺癌患者带来了新的希望[4-5]。

Abstract

In recent years, as women play a growing role in social families, the pressure also increases, leading to the increasing incidence of breast cancer. Breast cancer: female common diseases, the incidence of female malignant tumors first, is mainly the phenomenon of breast epithelial cells under the action of a variety of carcinogenic factors, need to actively carry out treatment as soon as possible, otherwise it can threaten the life safety of patients. Three negative breast cancer: mainly refers to the cancer tissue of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2) are negative breast cancer, can account for 15% -20% in all breast cancer, the most common type is invasive ductal carcinoma (medullary carcinoma, adenoid cystic carcinoma, metaplastic cancer), etc., the disease has high recurrence metastasis rate, short median survival, poor prognosis characteristics, is a difficult clinical treatment. Fortunately, we are diseases can be controlled by superb medical means and remove, gersand is the world's first approved targeted trophoblast cell surface antigen 2 antibody conjugated drugs, with high safety, significant curative effect, the advantage of less adverse reactions, it also brings new hope for three negative breast cancer patients [4-5].